title: Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia.
abstract: Vosaroxin is a first-in-class anticancer quinolone derivative that targets topoisomerase II and induces site-selective double-strand breaks in DNA, leading to tumor cell apoptosis. Vosaroxin has chemical and pharmacologic characteristics distinct from other topoisomerase II inhibitors due to its quinolone scaffold. The efficacy and safety of vosaroxin in combination with cytarabine were evaluated in patients with relapsed/refractory acute myeloid leukemia (AML) in a phase III, randomized, multicenter, double-blind, placebo-controlled study (VALOR). In this study, the addition of vosaroxin produced a 1.4-month improvement in median overall survival (OS; 7.5 months with vosaroxin/cytarabine vs. 6.1 months with placebo/cytarabine; hazard ratio [HR] 0.87, 95 % confidence interval [CI] 0.73-1.02; unstratified log-rank p [Formula: see text] 0.061; stratified log-rank p [Formula: see text]0.024), with the greatest OS benefit observed in patients ≥60 years of age (7.1 vs. 5.0 months; HR 0.75, 95 % CI 0.62-0.92; p [Formula: see text]0.003) and patients with early relapse (6.7 vs. 5.2 months; HR 0.77, 95 % CI 0.59-1.00; p [Formula: see text] 0.039), two AML patient groups that typically have poor prognosis. Here we review the chemical and pharmacologic properties of vosaroxin, how these properties are distinct from those of currently available topoisomerase II inhibitors, how they may contribute to the efficacy and safety profile observed in the VALOR trial, and the status of clinical development of vosaroxin for treatment of AML.
authors.affiliation: Sunesis Pharmaceuticals, Inc., South San Francisco, CA, USA.
authors.forename: Gene C
authors.initials: GC
authors.lastname: Jamieson
authors.affiliation: Sunesis Pharmaceuticals, Inc., South San Francisco, CA, USA.
authors.forename: Judith A
authors.initials: JA
authors.lastname: Fox
authors.affiliation: College of Pharmacy, Ohio State University, Columbus, OH, USA.
authors.forename: Ming
authors.initials: M
authors.lastname: Poi
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, Vanderbilt University, 2220 Pierce Avenue, 777 Preston Research Building, Nashville, TN, 37232, USA. stephen.strickland@Vanderbilt.Edu.
authors.forename: Stephen A
authors.initials: SA
authors.lastname: Strickland
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols; D003561:Cytarabine; D004311:Double-Blind Method; D000882:Haplorhini; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D051379:Mice; D008875:Middle Aged; D009287:Naphthyridines / Q000494:pharmacology / Q000627:therapeutic use*; D015363:Quinolones / Q000737:chemistry*; D051381:Rats; D013844:Thiazoles / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D009287:Naphthyridines; D015363:Quinolones; D013844:Thiazoles; D003561:Cytarabine; C485113:vosaroxin